Robustanic acid as a glutaminase and Na+, K+-ATPase inhibitor from leaves of Eucalyptus globulus-Reference-Cited by-同舟云学术

Robustanic acid as a glutaminase and Na⁺, K⁺-ATPase inhibitor from leaves of Eucalyptus globulus

Published:2024-07-03 Issue: Volume: Page:
ISSN:0939-5075
Container-title:Zeitschrift für Naturforschung C
language:en
Short-container-title:

Author:

Shimada Atsumi¹,Ueno Hiroshi²,Kawabata Kohei³,Inagaki Masanori³

Affiliation:

1. Division of Food and Nutrition , 73489 Nakamura Gakuen University Junior College , Fukuoka 814-0198 , Japan

2. Department of Medical Technology , Kawasaki University of Medical Welfare , Kurashiki , Okayama 701-0193 , Japan

3. Faculty of Pharmacy, Department of Pharmaceutical Chemistry , Yasuda Women’s University , Hiroshima 731-0153 , Japan

Abstract

Abstract This study was to compare glutaminase and Na+, K+-ATPase inhibitory activities of 20 herbal extracts and investigate the isolation, structural elucidation and those inhibitory activities of three triterpenes from the selected extract of Eucalyptus globulus Labill. Three triterpenes, ursolic acid (1), robustanic acid (2) and ursolic acid lactone (3), were identified by analyzing their NMR and MS spectral data and comparison of these with reported data. The IC50 values of 1–3 and the control compound against glutaminase, 6-diazo-5-oxo-l-norleucine (DON), were 443 μM, 334 μM, 963 μM and 134 μM, respectively. The IC50 values of 1, 2 and the control compound against Na+, K+-ATPase and ouabain, were 180 μM, 56 μM and 0.5 μM, respectively. Compounds 1 and 2 may serve as potential lead compounds for the prevention and treatment of neurodegenerative and lifestyle-related diseases by targeting glutaminase and Na+, K+-ATPase. This is the first report on glutaminase and Na+, K+-ATPase inhibitory activities of 2.

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/znc-2024-0071/pdf

Reference23 articles.

1. Thangavelu, K, Chong, QY, Low, BC, Sivaraman, J. Structural basis for the active site inhibition mechanism of human kidney-type glutaminase (KGA). Sci Rep 2014;4:3827–33. https://doi.org/10.1038/srep03827.

2. Sugiyama, K, Aida, T, Nomura, M, Takayanagi, R, Zeihofer, HU, Tanaka, K. Calpain-dependent degradation of nucleoporins contributes to motor neuron death in a mouse model of chronic excitotoxicity. J Neurosci 2017;37:8830–44, https://doi.org/10.1523/jneurosci.0730-17.2017.

3. Cheng, L, Wu, CR, Zhu, LH, Li, H, Chen, LX. Physapubescin, a natural withanolide as a kidney-type glutaminase (KGA) inhibitor. Bioorg Med Chem Lett 2017;27:1243–6. https://doi.org/10.1016/j.bmcl.2017.01.057.

4. Durante, W. The emerging role of L-glutamine in cardiovascular health and disease. Nutrients 2019;11:2092–107. https://doi.org/10.3390/nu11092092.

5. Koizumi, K, Nakagawa, T, Tobe, K, Igarashi, Y, Tsuneki, H, Sasaoka, T, inventors; Kyowa Hakko Bio Co. Ltd., assignee. Anti-inflammatory agent containing glutaminase inhibitor for medicine and health food. Japanese Patent No. 2020-29412A, 2020.